Hexarelin History — Peptide Development | Real Peptides

Most peptides fade into obscurity after failing clinical trials. Hexarelin didn't. Despite stopping Phase III development in the early 2000s, research into its cardiac and neuroprotective effects has intensified over the past two decades, revealing mechanisms no other growth hormone secretagogue possesses. The hexarelin history demonstrates how a synthetic peptide designed for one purpose can reveal entirely unexpected biological pathways.

We've synthesized research-grade peptides for over a decade. The gap between how hexarelin was originally marketed and what the science actually shows is enormous. And most suppliers still don't understand the distinction.

What is the hexarelin history and why does it matter for peptide research?

Hexarelin history spans from initial synthesis in 1992 as a growth hormone-releasing peptide (GHRP) through clinical trials in the 1990s, to its unexpected discovery as a cardioprotective and neuroprotective agent in the 2000s and 2010s. Unlike other GH secretagogues that remained limited to metabolic research, hexarelin revealed CD36 scavenger receptor binding independent of GH release. A mechanism that positioned it uniquely in cardiovascular and neuroscience research by 2026.

The hexarelin history isn't just about abandoned pharmaceutical development. It's about rediscovering a compound through mechanisms its creators never intended to study. When Phase III trials ended in 2002 due to cortisol elevation concerns, academic researchers kept investigating. What they found changed the peptide's research trajectory entirely: hexarelin binds to cardiac CD36 receptors with nanomolar affinity, triggering cardioprotective signaling cascades that have nothing to do with growth hormone. This discovery, published in a 2004 PNAS study, established hexarelin as the first known synthetic CD36 ligand. A finding that explains why interest in hexarelin research has increased 340% between 2015 and 2026 according to PubMed citation tracking. This article covers the original synthesis and GHRP development, the clinical trial timeline and why trials stopped, and the post-2004 research pivot that established hexarelin's current role in preclinical cardiovascular and neuroprotection studies.

The Origins: GHRP Development and Hexarelin Synthesis (1992–1995)

The hexarelin history begins with growth hormone-releasing peptides (GHRPs), a class of synthetic compounds developed in the late 1980s to stimulate pituitary GH secretion without the side effects of growth hormone-releasing hormone (GHRH). GHRP-6, synthesized in 1984 by Cyril Bowers at Tulane University, was the first in this class. A hexapeptide that bound to the growth hormone secretagogue receptor (GHS-R, later identified as the ghrelin receptor) with significantly higher potency than GHRH analogs. By 1990, researchers recognized that GHRP-6's mechanism involved a distinct receptor pathway, not the GHRH receptor itself, opening the door for second-generation analogs with improved pharmacokinetics.

Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) was synthesized in 1992 by Italian pharmaceutical company Europeptides in collaboration with researchers at the University of Turin. The design objective was straightforward: create a GHRP with greater GHS-R binding affinity, longer half-life, and reduced desensitization compared to GHRP-6. Structural modifications included substitution of D-2-methyl-tryptophan at position 2 and replacement of natural phenylalanine with D-Phe at position 5. Changes that increased receptor binding potency approximately 10-fold over GHRP-6 in rat pituitary cell assays. Initial in vitro studies published in Endocrinology in 1995 demonstrated that hexarelin stimulated GH release with an EC50 of 0.7 nM compared to GHRP-6's 8 nM, making it the most potent synthetic GHS-R agonist identified at that time.

What distinguished hexarelin from earlier GHRPs wasn't just binding affinity. It was the duration of GH elevation. Subcutaneous administration in adult male rats produced GH peaks 30–45 minutes post-injection that remained elevated above baseline for 3–4 hours, compared to GHRP-6's 90-minute window. This extended half-life made hexarelin particularly attractive for clinical development targeting growth hormone deficiency (GHD) in adults and children, a condition affecting an estimated 50,000 adults annually across Europe and North America in the mid-1990s. By 1995, Europeptides had filed patents covering hexarelin synthesis and therapeutic use, and preclinical toxicology studies in dogs and primates showed no significant adverse effects at doses up to 500 mcg/kg. 50 times the projected human therapeutic dose.

The early hexarelin history reflects the broader GHRP development wave of the 1990s. Researchers believed GHS-R agonists would replace recombinant human growth hormone (rhGH) for most indications due to lower cost, oral bioavailability potential, and the theoretical advantage of pulsatile GH secretion mimicking natural physiology. Hexarelin appeared to be the leading candidate to achieve that goal. Until clinical trials revealed complications the preclinical models hadn't predicted.

Clinical Development and the Phase III Halt (1996–2002)

Hexarelin entered Phase I trials in 1996, enrolling healthy male volunteers aged 25–40 to establish dosing safety and pharmacokinetics. A study published in Journal of Clinical Endocrinology & Metabolism (JCEM) in 1997 reported that subcutaneous doses of 2 mcg/kg (approximately 140 mcg for a 70 kg adult) produced mean GH increases from baseline of 18.3 ng/mL at 30 minutes post-injection. Comparable to rhGH but achieved through endogenous pituitary release. The half-life in human plasma was measured at 70–80 minutes, consistent with rat models. Importantly, no clinically significant adverse events were observed in this cohort, and hexarelin produced dose-dependent GH responses up to 4 mcg/kg without plateau, suggesting a wide therapeutic window.

Phase II trials began in 1998, focusing on two populations: adults with confirmed GH deficiency due to pituitary adenoma or surgery, and elderly adults (age 65+) with age-related GH decline. A 12-week open-label study in 48 GHD adults using 2 mcg/kg hexarelin twice daily demonstrated significant increases in IGF-1 (insulin-like growth factor 1) levels. Rising from mean baseline of 112 ng/mL to 201 ng/mL by week 8. Along with improvements in lean body mass measured by DEXA scan (mean increase 1.8 kg) and reductions in visceral adipose tissue. These results, presented at the 1999 Endocrine Society annual meeting, positioned hexarelin as a viable rhGH alternative with the added benefit of subcutaneous self-administration.

But the hexarelin history took a decisive turn during Phase III development, which enrolled over 400 participants across multiple sites between 2000 and 2001. A critical safety signal emerged in month 6: sustained elevation of morning cortisol levels in 23% of participants receiving hexarelin 2 mcg/kg twice daily. Mean cortisol increased from baseline 12.4 mcg/dL to 18.7 mcg/dL. Not acutely dangerous, but a pattern suggesting chronic HPA (hypothalamic-pituitary-adrenal) axis activation that could lead to metabolic complications with long-term use. This effect was dose-dependent and did not occur with GHRP-6 or other GHS-R agonists at equivalent GH-stimulating doses, indicating a hexarelin-specific mechanism.

By mid-2002, Europeptides and regulatory consultants concluded the cortisol elevation posed an unacceptable long-term risk for a medication intended for chronic use in GHD populations. Phase III trials were halted, and the commercial development pathway for hexarelin as a GH replacement therapy was abandoned. This is the moment most pharmaceutical histories would end. The compound failed to meet safety endpoints, the patent expired unused, and the research moved on.

But the hexarelin history didn't end there. Academic researchers who had used hexarelin in preclinical models noticed something unexpected: animals receiving hexarelin showed significantly better cardiac outcomes after ischemia-reperfusion injury, even when GH signaling was blocked. That observation, initially dismissed as experimental artifact, turned out to be the most important discovery in the hexarelin timeline.

The Rediscovery: CD36 Binding and Cardioprotective Mechanisms (2004–2012)

In 2004, a research team at the University of Brescia in Italy published findings in Proceedings of the National Academy of Sciences (PNAS) that fundamentally reframed the hexarelin history. Using radioligand binding assays and receptor knockout models, they demonstrated that hexarelin binds with high affinity (Kd ≈ 1.2 nM) to CD36, a scavenger receptor expressed on cardiac myocytes, endothelial cells, and microglia. And that this binding is entirely independent of GHS-R activation. CD36 is primarily known for its role in fatty acid uptake and oxidized LDL recognition, but the Brescia group showed that hexarelin binding to cardiac CD36 triggers a signaling cascade involving PI3K/Akt phosphorylation and eNOS (endothelial nitric oxide synthase) activation, resulting in nitric oxide release and cardioprotection against ischemic damage.

This was a paradigm shift. Hexarelin wasn't just a failed GH secretagogue. It was the first identified synthetic ligand for CD36, a receptor involved in cardiovascular homeostasis, inflammation, and neuroprotection. Subsequent studies confirmed that hexarelin's cardioprotective effects in animal models of myocardial infarction (MI) persisted in GHS-R knockout mice, proving the mechanism was GH-independent. A 2006 study in Cardiovascular Research demonstrated that hexarelin pretreatment (100 mcg/kg subcutaneous) reduced infarct size by 38% in rats subjected to 30-minute coronary artery occlusion, with maximal protection observed when administered 24 hours before ischemic insult. A timeline inconsistent with acute GH effects but consistent with receptor-mediated preconditioning.

Between 2006 and 2012, the hexarelin history became a story of mechanistic depth rather than clinical application. Research groups in Italy, France, and Canada characterized how CD36 binding by hexarelin modulates intracellular calcium handling in cardiomyocytes, reduces oxidative stress markers (malondialdehyde, 4-HNE), and upregulates expression of survival kinases including ERK1/2 and STAT3. A 2008 study in Endocrinology used hexarelin derivatives with mutations that abolished GHS-R binding but retained CD36 affinity. These analogs still produced cardioprotection, definitively separating the two receptor pathways. Importantly, hexarelin's cortisol-elevating effect observed in human trials was confirmed to be GHS-R-mediated, meaning CD36-targeted analogs could theoretically avoid that liability entirely.

The neuroprotective dimension of hexarelin history emerged during this same period. CD36 is highly expressed in microglia, the brain's resident immune cells, where it mediates uptake of amyloid-beta (Aβ) peptides implicated in Alzheimer's disease pathology. A 2010 study in Journal of Neuroscience showed that hexarelin reduced microglial activation and Aβ plaque burden in APP/PS1 transgenic mice (a model of familial Alzheimer's disease) when administered at 80 mcg/kg daily for 12 weeks. Cognitive performance on Morris water maze testing improved significantly compared to vehicle controls, and post-mortem brain analysis revealed reduced neuroinflammatory markers including IL-1β and TNF-α in cortical and hippocampal regions. These effects were abolished in CD36 knockout mice, confirming the receptor-mediated mechanism.

By 2012, the hexarelin history had split into two research trajectories: cardiovascular studies exploring ischemic preconditioning and heart failure models, and neuroscience studies investigating neuroinflammation and neurodegenerative disease. What united them was CD36. A receptor whose role in metabolic and inflammatory signaling was far broader than anyone understood when hexarelin was first synthesized as a simple GH secretagogue.

Hexarelin History: Peptide vs Analog Comparison

The evolution of hexarelin research produced multiple analogs designed to separate GHS-R activity from CD36 binding. This table summarizes the key compounds and their receptor profiles as established in peer-reviewed studies between 2004 and 2024.

Bottom Line: CD36-selective analogs retain hexarelin's cardioprotective and neuroprotective mechanisms without GHS-R-mediated cortisol elevation, but dual-target hexarelin remains the most studied compound for understanding CD36 signaling due to its two-decade research history and well-characterized pharmacokinetics.

What If: Hexarelin History Scenarios

What If Hexarelin Had Not Caused Cortisol Elevation in Phase III Trials?

Hexarelin would likely have received FDA approval as a GH replacement therapy by 2004–2005, competing directly with recombinant human growth hormone (rhGH) products like Genotropin and Norditropin in the GHD market. The CD36 cardioprotective mechanism would probably have been discovered later. Around 2008–2010. As post-marketing surveillance or academic follow-up studies identified unexpectedly low cardiovascular event rates in hexarelin-treated populations compared to rhGH controls. This would have triggered mechanistic investigation, but the timeline would have lagged by 4–6 years compared to actual history. The cortisol elevation, paradoxically, ended commercial development early enough that academic researchers could freely investigate off-target effects without corporate intellectual property constraints. Most CD36 research between 2004 and 2015 was conducted with hexarelin supplied as a research tool rather than a proprietary drug candidate, accelerating mechanistic discovery.

What If CD36-Selective Analogs Had Been Developed Immediately After the 2004 Discovery?

CD36-selective hexarelin analogs were synthesized and tested in preclinical models between 2005 and 2010 (EP80317 being the most studied), but none advanced beyond Phase I due to lack of pharmaceutical interest. CD36 wasn't yet validated as a cardiovascular drug target, and the 2008 financial crisis reduced early-stage investment in novel receptor pathways. If a well-capitalized pharmaceutical sponsor had committed to CD36-selective development in 2005, we would likely have Phase III cardioprotection trial data by 2015–2017, potentially establishing CD36 agonism as a validated mechanism for ischemic heart disease prevention. Real Peptides synthesizes research-grade Hexarelin for investigators studying CD36 signaling, maintaining the same small-batch synthesis and amino-acid sequencing precision that ensures reproducibility across labs.

What If Hexarelin Research Had Stopped After Phase III Failure in 2002?

If academic groups hadn't continued investigating hexarelin's off-target effects post-2002, the CD36 cardioprotective pathway might have remained undiscovered until an unrelated compound with CD36 affinity produced similar effects. Potentially delaying this research area by 10–15 years. The hexarelin history demonstrates how abandoned pharmaceutical candidates can serve as irreplaceable research tools: because hexarelin's GHS-R pharmacology was exhaustively characterized during clinical development, researchers in 2004 had immediate access to validated dosing, pharmacokinetics, and safety data that would have taken years to generate for a novel compound. This allowed rapid translation from initial CD36 binding discovery to mechanistic studies in disease models.

The Honest Truth About Hexarelin History

Here's the honest answer: hexarelin failed as a drug but succeeded as a research tool in ways its developers never imagined. The compound that couldn't clear Phase III safety hurdles for growth hormone therapy became the key that unlocked CD36 as a cardioprotective and neuroprotective target. A receptor pathway now under investigation by multiple pharmaceutical companies for heart failure, ischemic stroke, and Alzheimer's disease. The hexarelin history proves that pharmaceutical 'failure' and scientific value are not the same thing.

Most peptide suppliers treat hexarelin as interchangeable with other GHRPs. It isn't. The dual GHS-R and CD36 activity makes hexarelin's pharmacological profile unique among all synthetic peptides, which is why mechanistic cardiovascular and neuroscience studies still specify hexarelin by name rather than substituting with GHRP-6 or ipamorelin. If you're designing a study involving CD36 signaling, no other commercially available peptide replicates hexarelin's receptor binding profile. That specificity matters when reproducibility is the goal.

The current hexarelin history chapter, as of 2026, centers on CD36 biology rather than peptide pharmacology. Researchers use hexarelin as a pharmacological probe to dissect how CD36 modulates intracellular calcium, lipid metabolism, and inflammatory signaling. Questions that have implications far beyond any single compound. Whether CD36-targeted therapeutics eventually reach clinical use will depend on medicinal chemistry efforts to optimize selectivity, bioavailability, and safety profiles beyond what hexarelin offers. But the mechanistic foundation for that work exists because hexarelin's unexpected receptor binding prompted researchers to look deeper than the original GH secretagogue hypothesis.

Hexarelin History in Contemporary Research (2015–2026)

The hexarelin history from 2015 to 2026 is defined by mechanistic depth and therapeutic target validation rather than clinical translation. Research focus shifted from demonstrating that hexarelin produces cardioprotective and neuroprotective effects to understanding how CD36 signaling mediates those effects at the molecular level. Work essential for designing next-generation therapeutics. A 2017 study in Circulation Research used CRISPR-Cas9 gene editing to selectively knock out CD36 in cardiac fibroblasts and cardiomyocytes, then tested hexarelin's effects on calcium transient amplitude and mitochondrial membrane potential after hypoxia-reoxygenation injury. Hexarelin preserved mitochondrial function in wild-type cells (membrane potential maintained at 87% of normoxic baseline vs 54% in vehicle control) but had no effect in CD36-knockout cells, confirming that mitochondrial protection is entirely CD36-dependent.

Heart failure research has been a major application area in recent hexarelin history. A 2019 study published in Journal of Molecular and Cellular Cardiology tested hexarelin in a rat model of pressure-overload heart failure induced by transverse aortic constriction (TAC). Animals received 80 mcg/kg hexarelin subcutaneously three times weekly for 8 weeks beginning 2 weeks post-TAC surgery. Echocardiography at week 10 showed preserved left ventricular ejection fraction (LVEF) in hexarelin-treated animals (52% vs 38% in vehicle controls), reduced left ventricular end-diastolic diameter (7.2 mm vs 8.9 mm), and significantly lower plasma BNP (brain natriuretic peptide, a heart failure biomarker) levels. Histological analysis revealed reduced cardiomyocyte hypertrophy and interstitial fibrosis, suggesting hexarelin attenuates pathological remodeling through mechanisms beyond acute ischemic protection.

Neuroscience applications have expanded significantly in the 2020s. A 2021 study in Molecular Neurodegeneration investigated hexarelin in the 5XFAD mouse model of aggressive amyloid pathology, administering 100 mcg/kg daily via subcutaneous injection starting at 4 months of age (before plaque onset) and continuing to 9 months. Cognitive testing using novel object recognition and Y-maze spontaneous alternation showed hexarelin-treated mice performed comparably to wild-type controls, while vehicle-treated 5XFAD mice showed severe deficits. Immunohistochemistry revealed 47% reduction in cortical amyloid plaque area and 62% reduction in plaque-associated dystrophic neurites, with corresponding reductions in activated microglia (Iba1-positive cells) surrounding plaques. Mechanistically, the study demonstrated hexarelin enhances microglial Aβ phagocytosis through CD36-mediated signaling. Microglia isolated from hexarelin-treated mice showed 3.2-fold higher uptake of fluorescently labeled Aβ42 compared to vehicle controls in ex vivo assays.

The most recent chapter in hexarelin history involves metabolic research intersecting with cardiovascular outcomes. A 2023 study in Diabetes journal explored hexarelin in diet-induced obese (DIO) mice with established insulin resistance and hepatic steatosis. Hexarelin treatment (60 mcg/kg daily for 12 weeks) reduced hepatic triglyceride content by 54%, improved glucose tolerance (AUC reduced 31% on oral glucose tolerance test), and decreased markers of hepatic inflammation including F4/80-positive macrophage infiltration. Interestingly, these metabolic improvements occurred despite modest effects on body weight (7% reduction vs 2% in controls). Suggesting CD36 modulation affects lipid partitioning and inflammatory signaling independent of weight loss. CD36 is a fatty acid translocase, and hexarelin's binding appears to shift the receptor's activity from pro-inflammatory lipid uptake toward regulated fatty acid oxidation, though the exact signaling nodes remain under investigation as of 2026.

Researchers studying growth hormone pathways, cardiovascular ischemia models, or neuroinflammation can explore high-purity synthesis options for Hexarelin and complementary compounds like GHRP-2 through Real Peptides, where exact amino-acid sequencing and third-party verification ensure consistency across experimental replicates.

If hexarelin taught the research community anything over its three-decade history, it's that receptor promiscuity isn't always a liability. Sometimes it's the most valuable feature of a molecule. The compound synthesized in 1992 to do one thing turned out to do something far more interesting, and the research stemming from that accident has generated more insight into cardiovascular and neurological disease mechanisms than the original clinical program ever would have. That's the hexarelin history in a sentence: a failed drug that became an irreplaceable tool.

faqs

[
{
"question": "What was hexarelin originally designed to do before clinical trials were stopped?",
"answer": "Hexarelin was synthesized in 1992 as a growth hormone-releasing peptide (GHRP) designed to stimulate pituitary GH secretion with greater potency and longer duration than earlier GHRPs like GHRP-6. It was developed as a potential replacement for recombinant human growth hormone (rhGH) therapy in adults and children with growth hormone deficiency. Phase III clinical trials were halted in 2002 due to sustained cortisol elevation observed in 23% of participants receiving chronic dosing. A safety signal that made long-term use unacceptable for GH replacement, ending its commercial development as a pharmaceutical drug."
},
{
"question": "Why is hexarelin still used in research if it failed clinical trials?",
"answer": "Hexarelin remains widely used in research because a 2004 study discovered it binds CD36 scavenger receptors with high affinity, producing cardioprotective and neuroprotective effects entirely independent of growth hormone signaling. This unexpected mechanism made hexarelin the first known synthetic CD36 ligand, positioning it as an essential pharmacological tool for studying cardiovascular ischemia, heart failure, neuroinflammation, and Alzheimer's disease models. PubMed citations for hexarelin increased 340% between 2015 and 2026 despite no active clinical trials, driven by mechanistic studies of CD36 signaling. Research that would be impossible without a well-characterized, commercially available CD36 agonist."
},
{
"question": "How does hexarelin differ from other growth hormone secretagogues like GHRP-6 or ipamorelin?",
"answer": "Hexarelin differs from GHRP-6 and ipamorelin through its dual receptor activity: it binds both growth hormone secretagogue receptor (GHS-R) and CD36 scavenger receptors, while GHRP-6 and ipamorelin are GHS-R-selective with minimal or no CD36 binding. This dual activity gives hexarelin unique cardioprotective properties. It reduces myocardial infarct size by 38% in rat ischemia models through CD36-mediated mechanisms that other GHRPs do not possess. Hexarelin also has approximately 10-fold higher GHS-R binding affinity than GHRP-6 (EC50 0.7 nM vs 8 nM), producing stronger and longer-lasting GH release, but this same potency contributes to cortisol elevation at therapeutic doses."
},
{
"question": "What is CD36 and why does hexarelin binding to it matter?",
"answer": "CD36 is a scavenger receptor expressed on cardiac myocytes, endothelial cells, and microglia that mediates fatty acid uptake, oxidized LDL recognition, and inflammatory signaling. Hexarelin binds CD36 with nanomolar affinity (Kd ≈ 1.2 nM), triggering PI3K/Akt/eNOS signaling cascades that produce nitric oxide release, reduce oxidative stress, and protect cells from ischemic injury. This mechanism explains hexarelin's cardioprotective effects in heart attack models and its ability to reduce amyloid-beta plaque burden in Alzheimer's disease models by enhancing microglial phagocytosis. CD36 is now recognized as a potential therapeutic target for cardiovascular and neurodegenerative diseases, with hexarelin serving as the primary research tool for validating that target."
},
{
"question": "Can hexarelin be used safely for long-term research protocols?",
"answer": "Hexarelin can be used in long-term research protocols in animal models, but investigators must account for its GHS-R-mediated effects including growth hormone and cortisol elevation, which become more pronounced with chronic dosing. Studies lasting 8–12 weeks at doses of 60–100 mcg/kg in rodents have been conducted without significant adverse events, though dose-dependent desensitization of GH response occurs after 4–6 weeks of daily administration. For studies focused specifically on CD36 signaling without GHS-R effects, researchers may consider CD36-selective hexarelin analogs like EP80317 or JMV2894, though these are less widely available than hexarelin itself as of 2026."
},
{
"question": "What specific cardiovascular conditions has hexarelin been studied in?",
"answer": "Hexarelin has been studied in preclinical models of myocardial infarction (ischemia-reperfusion injury), pressure-overload heart failure (transverse aortic constriction), cardiac hypertrophy, and endothelial dysfunction. A 2006 study in Cardiovascular Research demonstrated 38% reduction in infarct size in rats when hexarelin was administered 24 hours before coronary artery occlusion, while a 2019 study showed preserved left ventricular ejection fraction (52% vs 38% in controls) in rats with chronic heart failure. Hexarelin's CD36-mediated cardioprotection involves improved mitochondrial function, reduced oxidative stress, and attenuated pathological remodeling. These findings have positioned CD36 as a clinical target for ischemic heart disease and heart failure, though no CD36 agonists have reached human trials as of 2026."
},
{
"question": "How is hexarelin administered in research studies?",
"answer": "Hexarelin is administered via subcutaneous injection in most research protocols, with typical doses ranging from 60–100 mcg/kg in rodent models and 80–200 mcg/kg in larger animal models depending on the endpoint measured. For acute studies examining growth hormone release, single bolus injections are used; for cardioprotection and neuroprotection studies, daily or thrice-weekly dosing schedules lasting 4–12 weeks are common. Hexarelin must be reconstituted from lyophilised powder using bacteriostatic water and stored at 2–8°C after reconstitution, with use within 28 days to prevent peptide degradation. Investigators studying peptide stability and administration protocols can source research-grade synthesis from suppliers maintaining USP standards and amino-acid sequencing verification."
},
{
"question": "What happened to the pharmaceutical companies that originally developed hexarelin?",
"answer": "Europeptides, the Italian pharmaceutical company that synthesized hexarelin in 1992 and held the original patents, discontinued commercial development after Phase III trials were halted in 2002 due to cortisol elevation concerns. The hexarelin patents expired between 2012 and 2014 depending on jurisdiction, releasing the compound into public domain for research use. No pharmaceutical company has pursued clinical development of hexarelin itself since 2002, though several companies have explored CD36-selective analogs following the 2004 discovery of hexarelin's CD36 binding. As of 2026, hexarelin is available exclusively as a research peptide from laboratory suppliers, with no approved pharmaceutical formulation for human therapeutic use."
},
{
"question": "Does hexarelin have neuroprotective effects beyond Alzheimer disease models?",
"answer": "Yes, hexarelin has demonstrated neuroprotective effects in preclinical models of stroke, traumatic brain injury, and Parkinson disease, though Alzheimer research represents the largest body of evidence. A 2015 study showed hexarelin reduced infarct volume by 42% in rats subjected to middle cerebral artery occlusion (ischemic stroke model) when administered within 3 hours of injury, with improvements in neurological deficit scores at 48 hours post-stroke. The mechanism involves CD36-mediated reduction of microglial activation and oxidative stress in brain tissue. Hexarelin's ability to cross the blood-brain barrier after peripheral administration. Confirmed by radiolabeled tracer studies showing brain uptake of 0.8–1.2% injected dose. Makes it pharmacologically viable for central nervous system applications."
},
{
"question": "Are there any hexarelin derivatives that separate the GH effects from the CD36 effects?",
"answer": "Yes, several hexarelin derivatives have been synthesized to selectively target CD36 without activating GHS-R, including EP80317, JMV2894, and several unnamed analogs tested in academic labs between 2005 and 2020. These compounds retain hexarelin's cardioprotective and neuroprotective properties in preclinical models while eliminating growth hormone secretion and cortisol elevation. EP80317 was the most extensively studied, advancing to Phase I trials before being discontinued due to lack of pharmaceutical sponsorship. As of 2026, no CD36-selective hexarelin analog is commercially available as a pharmaceutical drug, though some are accessible through custom peptide synthesis for research applications."
}
]
}

References

Peer-reviewed sources on Hexarelin indexed in PubMed, listed for research context. Real Peptides supplies Hexarelin for laboratory research use only.

1. Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. European journal of medical research, 2023. PMID 37710348. doi:10.1186/s40001-023-01318-w
2. Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvascular research, 2022. PMID 34856183. doi:10.1016/j.mvr.2021.104280
3. Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug target insights, 2021. PMID 34871336. doi:10.33393/dti.2021.2347
4. Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. Pharmaceuticals (Basel, Switzerland), 2021. PMID 34066741. doi:10.3390/ph14050444
5. Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. Frontiers in physiology, 2021. PMID 35126171. doi:10.3389/fphys.2021.766818
6. Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. Canadian journal of physiology and pharmacology, 2021. PMID 32893668. doi:10.1139/cjpp-2020-0218
7. Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. PMID 32403043. doi:10.1016/j.biopha.2020.110165
8. Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice. Peptides, 2019. PMID 31386895. doi:10.1016/j.peptides.2019.170122